Je was op zoek naar: 1619 (Fins - Engels)

1619 artikla
article 1619

emea/ cpmp/ bpwg/ 1619/ 99
emea/ cpmp/ bpwg/1619/99

3-kinuklidinoli (1619–34–7)
3-quinuclidinol (1619-34-7);

(tiedoksiannettu numerolla k(2004) 1619)
(notified under document number c(2004) 1619)

kinuklinidin-3-oli (1619-34-7)
quinuclidin-3-ol (1619-34-7);

esittelijä: mário soares (cese 1619/2008)
rapporteur: mr soares (cese 1619/2008)

komission asetus (ey) n:o 1619/2004,
commission regulation (ec) no 1619/2004

1619 jätteiden kierrätys, radioaktiivinen jäte, säteilysuojelu, voimalaitosten käytöstäpoistaminen
ec countries, multinational corporation, restriction on competition, size of business

950 euroa tonnilta ilmateitse kaupan pidettävää tonnikalaa enintään 1619 tonnin vuosittaista määrää kohden;
eur 950 per tonne of tuna marketed by air for up to 1619 tonnes a year;

lähtien 09/13/2015 ( 10 kuukautta sitten - 1619 osumaa)
since 09/13/2015 ( 10 months ago - 1617 hits)

cavalieri hakenut johdolla matematiikan bolognassa vuonna 1619, mutta ei onnistunut, koska hän oli liian nuori, joka kantaa tämän virkaiän.
cavalieri applied for the chair of mathematics in bologna in 1619 but was not successful since he was considered too young for a position of this seniority.

1 administration (ivig) core spc for human plasma derived and emea/cpmp/bpwg/1619/99 recombinant coagulation factor viii hyväksytty kesäkuussa 2000 products core spc for human plasma derived and emea/cpmp/bpwg/1625/99 hyväksytty kesäkuussa 2000 recombinant coagulation factor ix products note for guidance on the clinical emea/cpmp/bpwg/198/95 rev. 1 investigation of human plasma derived hyväksytty lokakuussa 2000 factor viii and ix products note for guidance on the clinical emea/cpmp/bpwg/1561/99 investigation of recombinant factor viii hyväksytty lokakuussa 2000 and ix products emea/cpmp/phvwp/bpwg/core spc for human albumin hyväksytty lokakuussa 2000 2231/99
emea/cpmp/bpwg/1561/99emea/cpmp/phvwp/bpwg/2231/99 emea/cpmp/bpwg/2220/99emea/cpmp/bpwg/3226/99cpmp efficacy working party reference number emea/cpmp/ewp/519/98 emea/cpmp/ewp/197/99emea/cpmp/ewp/570/98emea/cpmp/ewp/2922/99emea/cpmp/ewp/2863/99emea/cpmp/ewp/707/98emea/cpmp/ewp/612/00emea/cpmp/ewp/2655/99emea/cpmp/ewp/482/99 emea/cpmp/ewp/1080/00emea/cpmp/ewp/565/98emea/cpmp/ewp/785/97emea/cpmp/ewp/566/98 rev.1emea/cpmp/ewp/2284/99emea general report 2000core spc for human albumin adopted october 2000 note for guidance on the clinical investigation of human plasma derived factor viii and ix products released for consultation june 2000 note for guidance on the clinical investigation of recombinant factor viii and ix products released for consultation june 2000 core spc for human albumin released for consultation june 2000 note for guidance on the clinical investigation of plasma derived antithrombin products released for consultation december 2000 core spc for human plasma derived antithrombin released for consultation december 2000